These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 24366691)
1. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Gil del Alcazar CR; Hardebeck MC; Mukherjee B; Tomimatsu N; Gao X; Yan J; Xie XJ; Bachoo R; Li L; Habib AA; Burma S Clin Cancer Res; 2014 Mar; 20(5):1235-48. PubMed ID: 24366691 [TBL] [Abstract][Full Text] [Related]
2. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Mukherjee B; Tomimatsu N; Amancherla K; Camacho CV; Pichamoorthy N; Burma S Neoplasia; 2012 Jan; 14(1):34-43. PubMed ID: 22355272 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cerniglia GJ; Karar J; Tyagi S; Christofidou-Solomidou M; Rengan R; Koumenis C; Maity A Mol Pharmacol; 2012 Dec; 82(6):1230-40. PubMed ID: 22989521 [TBL] [Abstract][Full Text] [Related]
4. ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration. Fròsina G; Profumo A; Marubbi D; Marcello D; Ravetti JL; Daga A Radiat Oncol; 2018 Apr; 13(1):76. PubMed ID: 29685176 [TBL] [Abstract][Full Text] [Related]
5. NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro. Wang WJ; Long LM; Yang N; Zhang QQ; Ji WJ; Zhao JH; Qin ZH; Wang Z; Chen G; Liang ZQ Acta Pharmacol Sin; 2013 May; 34(5):681-90. PubMed ID: 23603977 [TBL] [Abstract][Full Text] [Related]
6. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization. Kuger S; Flentje M; Djuzenova CS Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922 [TBL] [Abstract][Full Text] [Related]
8. Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy. Agliano A; Balarajah G; Ciobota DM; Sidhu J; Clarke PA; Jones C; Workman P; Leach MO; Al-Saffar NMS Oncotarget; 2017 Jul; 8(29):47969-47983. PubMed ID: 28624789 [TBL] [Abstract][Full Text] [Related]
9. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer. Chen YH; Wei MF; Wang CW; Lee HW; Pan SL; Gao M; Kuo SH; Cheng AL; Teng CM Cancer Lett; 2015 Feb; 357(2):582-90. PubMed ID: 25497009 [TBL] [Abstract][Full Text] [Related]
10. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Fokas E; Yoshimura M; Prevo R; Higgins G; Hackl W; Maira SM; Bernhard EJ; McKenna WG; Muschel RJ Radiat Oncol; 2012 Mar; 7():48. PubMed ID: 22452803 [TBL] [Abstract][Full Text] [Related]
11. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Mukherjee B; McEllin B; Camacho CV; Tomimatsu N; Sirasanagandala S; Nannepaga S; Hatanpaa KJ; Mickey B; Madden C; Maher E; Boothman DA; Furnari F; Cavenee WK; Bachoo RM; Burma S Cancer Res; 2009 May; 69(10):4252-9. PubMed ID: 19435898 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660 [TBL] [Abstract][Full Text] [Related]
13. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Santiskulvong C; Konecny GE; Fekete M; Chen KY; Karam A; Mulholland D; Eng C; Wu H; Song M; Dorigo O Clin Cancer Res; 2011 Apr; 17(8):2373-84. PubMed ID: 21372221 [TBL] [Abstract][Full Text] [Related]
14. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154 [TBL] [Abstract][Full Text] [Related]
15. NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells. Vazquez N; Lopez A; Cuello V; Persans M; Schuenzel E; Innis-Whitehouse W; Keniry M Cancer Treat Res Commun; 2021; 27():100340. PubMed ID: 33636591 [TBL] [Abstract][Full Text] [Related]
16. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma. Yang F; Qian XJ; Qin W; Deng R; Wu XQ; Qin J; Feng GK; Zhu XF PLoS One; 2013; 8(3):e59879. PubMed ID: 23533654 [TBL] [Abstract][Full Text] [Related]
17. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Liu TJ; Koul D; LaFortune T; Tiao N; Shen RJ; Maira SM; Garcia-Echevrria C; Yung WK Mol Cancer Ther; 2009 Aug; 8(8):2204-10. PubMed ID: 19671762 [TBL] [Abstract][Full Text] [Related]
18. Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability. Seo BR; Min KJ; Cho IJ; Kim SC; Kwon TK PLoS One; 2014; 9(4):e95588. PubMed ID: 24743574 [TBL] [Abstract][Full Text] [Related]
19. Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control. Golding SE; Rosenberg E; Adams BR; Wignarajah S; Beckta JM; O'Connor MJ; Valerie K Cell Cycle; 2012 Mar; 11(6):1167-73. PubMed ID: 22370485 [TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Maira SM; Stauffer F; Brueggen J; Furet P; Schnell C; Fritsch C; Brachmann S; Chène P; De Pover A; Schoemaker K; Fabbro D; Gabriel D; Simonen M; Murphy L; Finan P; Sellers W; García-Echeverría C Mol Cancer Ther; 2008 Jul; 7(7):1851-63. PubMed ID: 18606717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]